Ricevi le ultime notizie sulle azioni Capricor Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CAPR

Ultime notizie per

CAPRICOR THERAPEUTICS INC

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

Capri Holdings Ltd

CAPRAL LTD by Capral Ltd.

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

Press Releases

CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

News

Legal

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Health Care

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

CAPR

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Avalo Therapeutics

Benitec Biopharma

Candel Therapeutics

Crescent Biopharma

Cellectis S.A. - American Depositary Shares

Cellectis

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

enGene Holdings

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

ETHZilla

Humacyte

Korro Bio

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Puma Biotechnology

PepGen

Pyxis Oncology

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Capricor Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO